Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs
Hamdy, S., Agwa, S., Afify, A., Mohmmed, A., Ali, B. (2020). Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs. EKB Journal Management System, 16(1), 109-119. doi: 10.21608/blj.2020.146604
Soha M. Hamdy; Sara H. A. Agwa; Ahmed A. G. Afify; Amany M. Mohmmed; Basma M. M. Ali. "Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs". EKB Journal Management System, 16, 1, 2020, 109-119. doi: 10.21608/blj.2020.146604
Hamdy, S., Agwa, S., Afify, A., Mohmmed, A., Ali, B. (2020). 'Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs', EKB Journal Management System, 16(1), pp. 109-119. doi: 10.21608/blj.2020.146604
Hamdy, S., Agwa, S., Afify, A., Mohmmed, A., Ali, B. Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs. EKB Journal Management System, 2020; 16(1): 109-119. doi: 10.21608/blj.2020.146604

Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs

Biochemistry Letters
Article 9, Volume 16, Issue 1, 2020, Page 109-119  XML PDF (513.24 K)
Document Type: Original Article
DOI: 10.21608/blj.2020.146604
View on SCiNiTO View on SCiNiTO
Authors
Soha M. Hamdy1; Sara H. A. Agwa2; Ahmed A. G. Afify3; Amany M. Mohmmed4; Basma M. M. Ali5
1Professor of Bio chemistry, Chemistry Department, Faculty of Science, Fayoum University
2Assistant consultant of clinical pathology& molecular biology in the HCV research and treatment unit in Faculty of Medicine, Medical Ain Shams Research Institute (MASRI), Cairo-Egypt
3Professor of Tropical Medicine, Gastroenterology Department, Faculty of Medicine, Fayoum University
4Assistant Professor of Biochemistry, Chemistry Department, Faculty of Science, Fayoum University
5Demonstrator of Biochemistry, Chemistry Department, Faculty of Science, Fayoum University
Abstract
Hepatitis C viral infection is with the highest prevalence rate in Egypt. Direct Acting Antivirals (DAAs) is now the standard of care for HCV infection treatment. Here we assess the predictive value of single-nucleotide polymorphisms (SNP) rs2596542 C/T in chromosome 6 located in MHC class I on the response to DAAs in chronic HCV infected Egyptian patients. This study was performed on 70 Egyptian patients positive for HCV; classified into two groups. Group I: (33 patients) were received combination therapy Sofosbuvir (Sovaldi) 400 mg/day plus Declatasvir 60 mg once daily, Group II: (37 patients) were received Ombitasvir 25 mg, Paritaprevir 150 mg and Ritonavir 100 mg/day plus Ribavirin 15 mg/kg/day for 12 weeks. HCV level by (RT-PCR), MICA single nucleotide polymorphism of rs2596542, ALT, AST, total bilirubin, serum albumin, fasting blood sugar,  HbA1C %, CBC, serum creatinine, AFP were performed in all volunteer patients. Results showed that group II responded with 100% in CT- SNP genotype. However both CC and TT- SNP genotypes responded with 83.33% and 91.67% respectively. There was no observed significant association between SNP rs2596542 C/T and all clinical parameters except AFP that give positive significant correlation in the CC genotype.
Keywords
Single nucleotide polymorphism (SNP); DDAs; HCV
Statistics
Article View: 172
PDF Download: 174